Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1993-12-17
2000-08-22
Mertz, Prema
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
424 852, 530351, 514 2, 514 8, 514 12, 514885, A61K 4505
Patent
active
061068233
ABSTRACT:
A method is provided for treating tumors, e.g., lymphocytic leukemias, which comprises administering to a mammal an effective amount of interleukin-10.
REFERENCES:
patent: 5328989 (1994-07-01), Vellekamp et al.
patent: 5368854 (1994-11-01), Rennick
Balkwill et al (1989) Immunol. Today 10(9), 299-304.
ATCC Cell Lines and Hybridomas Catalog, 1992, 7.sup.th Edition, Amer. Type Culture Collection, Rockville, MD, p. 287.
Richter et al., Cancer Res. 53:4134-4137 (1993).
Spits et al., Int. Arch. Allergy Immunol. 99:8-15 (1992).
Rene de Waal Malefyt et al., "Interleukin-10," Current Opinion in Immunology, vol. 4, pp. 314-320, 1992.
Rene de Waal Malefyt et al., "Interleukin-10 (IL-10) Inhibits Cytokine Synthesis by Human Monocytes: An Autoregulatory Role of IL-10 Produced by Monocytes," J. Exp. Med., vol. 174, pp. 1209-1220, Nov. 1991.
Rene de Waal Malefyt et al., "IL-10 Directly Inhibits IL-2 Transcription by Human PBL T Cells, Th0, Th1 and Th2 Clones," Abstract for the International Congress of Immunology in Budapest, Hungary, Aug. 1992.
Thierry Defrance, et al., "Interleukin 10 and Transforming Growth Factor .beta. Cooperate to Induce Anti-CD40-activated Naive Human B Cells to Secrete Immunoglobulin A," J. Exp. Med., vol. 175, pp. 671-682, Mar. 1992.
Dighiero, et al., "B-Cell Chronic Lymphocytic Leukemia: Present Status and Future Directions," Blood, vol. 78, pp. 1901-, 1991.
Ning Fei Go, et al., "Interleukin 10, a Novel B Cell Stimulatory Factor: Unresponsiveness of X Chromosome-linked Immunodeficiency B Cells," J. Exp. Med., vol. 172, pp. 1625-1631, Dec. 1990.
Di-Hwei Hsu, et al., "Expression of Interleukin-10 Activity by Epstein-Barr Virus Protein BCRF1," Science, vol. 250, pp. 830-832, Nov. 1990.
Ian A. MacNeil, et al., "IL-10, a Novel Growth Cofactor for Mature and Immature T Cells," J. Immunol., vol. 145, pp. 4167-4173, 1990.
Fran.cedilla.oise Rousset, et al., "Interleukin 10 Is a Potent Growth and Differentiation Factor for Activated Human B Lymphocytes," Proc. Natl. Acad. Sci. USA, vol. 89, pp. 1890-1893, Mar. 1992.
Robert I. Tepper, et al., "Murine Interleukin-4 Displays Potent Anti-Tumor Activity in Vivo," Cell, vol. 57, pp. 503-512, 1989.
Whicher, et al., Clinical Chemistry, vol. 36, No. 7, pp. 1269-1281, 1990.
Fiorentino, et al., "IL-10 Acts on the Antigen-presenting Cell to Inhibit Cytokine Production by the Th1 Cells," The Journal of Immunology, vol. 146, No. 10, pp. 3444-3452, May 15, 1991.
Thompson-Snipes, et al., "Interleukin 10: A Novel Stimulatory Factor for Mast Cells and their Progenitors," J. Exp. Med., vol. 173, pp. 507-510, Feb., 1991.
MacNeil, et al., "IL-10, A Novel Growth Cofactor for Mature and Immature T Cells," The Journal of Immunology, vol. 145, No. 12, pp. 4167-4173, Dec. 15, 1990.
O'Garra, et al., "Production of Cytokines by Mouse B Cells: B Lymphomas and Normal B Cells Produce Interleukin 10," International Immunology, vol. 2, No. 9, pp. 821-832, Jun. 4, 1990.
Chen, et al., "IL-10: A Novel Cytotoxic T Cells Differentiation Factor," The Journal of Immunology, vol. 147, No. 2, pp 528-534, Jul. 15, 1991.
de Waal Malfeyt, et al., "Interleukin 10 (IL-10) and Viral IL-10 Strongly Reduce Antigen-specific Human T Cell Proliferation by Diminishing the Antigen-presenting Capacity of Monocytes via Downregulation of Class II Major Histocompatibility Complex Expression," Journal of Experimental Medicine, vol. 174, pp. 915-924, Oct., 1991.
Spits, et al., "Alloantigen Recognition Is Preceded by Nonspecific Adhesion of Cytotoxic T Cells and Target Cells," Science, vol. 232 pp. 403-405, Apr., 1986.
Shaw, et al., "Two Antigen-independent Adhesion Pathways used by Human Cytotoxic T-Cell Clones," Nature, vol. 323, pp. 262-264, Sep. 18, 1986.
Azuma, et al., "CD28 Interaction with B7 Costimulates Primary Allogeneic Proliferative Responses and Cytotoxicity Mediated by Small, Resting T Lymphocytes," J. Exp. Med., vol. 175, pp. 353-359, Feb., 1992.
Ning Fei Go, et al., "Interleukin 10, A Novel B Cell Stimulatory Factor: Unresponsiveness of X Chromosome-Linked Immunodeficiency B Cells," J. of Exp. Med., 172(6):1625-1631, Dec. 1990.
Banchereau Jacques
de Vries Jan E.
de Waal Malefyt Rene
Fluckiger Anne-Catherine
Moore Kevin W.
Mertz Prema
Schering Corporation
Schram David B.
LandOfFree
Treatment of neoplastic disease with interleukin-10 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of neoplastic disease with interleukin-10, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of neoplastic disease with interleukin-10 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-577495